Results 41 to 50 of about 27,235 (300)

Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of ‘Almost Natural’ Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection

Frontiers in Immunology, 2022
A subset of antibodies found in cattle comprises ultralong CDR-H3 regions of up to 70 amino acids. Interestingly, this type of immunoglobulin usually pairs with the single germline VL gene, V30 that is typically very conserved in sequence.
Daniel Klewinghaus, Lukas Pekar, Paul Arras, Simon Krah, Bernhard Valldorf, Harald Kolmar, Stefan Zielonka   +6 more
doaj   +1 more source

Recent Advances in mRNA Delivery Systems for Cancer Therapy

Advanced Science, EarlyView.
This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang, Ya‐Nan Fan, Si‐Qi Jiang, Ya‐Jing Ma, Yao‐Ru Yu, Yu‐Xin Qing, Qian‐Ru Li, Yi‐Lin Liu, Song Shen, Jun Wang   +9 more
wiley   +1 more source

A mechanistic quantitative systems pharmacology model platform for translational efficacy evaluation and checkpoint combination design of bispecific immuno-modulatory antibodies

Frontiers in Pharmacology
Over the past 2 decades, tumor immunotherapies have witnessed remarkable advancements, especially with the emergence of immune checkpoint-targeting bispecific antibodies.
Yiyang Xu, Siyuan Yang, Qi Rao, Yuan Gao, Guanyue Zhou, Dongmei Zhao, Xinsheng Shi, Yi Chai, Chen Zhao, Chen Zhao   +9 more
doaj   +1 more source

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?

Antibodies, 2015
As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies ...
Joanie Del Bano, Patrick Chames, Daniel Baty, Brigitte Kerfelec   +3 more
doaj   +1 more source

Intein mediated high throughput screening for bispecific antibodies

mAbs, 2020
Bispecific antibodies comprise extremely diverse architectures enabling complex modes of action, such as effector cell recruitment or conditional target modulation via dual targeting, not conveyed by monospecific antibodies.
Tim Hofmann, Johannes Schmidt, Elke Ciesielski, Stefan Becker, Thomas Rysiok, Mark Schütte, Lars Toleikis, Harald Kolmar, Achim Doerner   +8 more
doaj   +1 more source

CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies

mAbs, 2022
As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies, is critical to the advancement of the field.
Monica L. Fernández-Quintero, Katharina B. Kroell, Lukas J. Grunewald, Anna-Lena M. Fischer, Jakob R. Riccabona, Klaus R. Liedl   +5 more
doaj   +1 more source

Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer

Advanced Science, EarlyView.
This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan, Kun Shao, Roopa Hebbandi Nanjundappa, Daniel‐Jiajun Yu, Marianne Stanford, Huile Gao, Channakeshava Sokke Umeshappa   +6 more
wiley   +1 more source

An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy

Advanced Science, EarlyView.
This study develops a dimeric T cell receptor engager protein specific for tumor KRAS‐G12V mutation. The engager proteins are capable of mediating the formation of synapse between T cell and tumor cell and demonstrate substantial tumor suppression efficacy.
Keke Ma, Jie Wang, Min Jiang, Juanhua He, Fangyang Li, Dan Lu, Chao Su, Yan Chai, Wenjing Jin, Yu Chen, Catherine W.H. Zhang, Xiaopeng Ma, Hui Tan, George F. Gao, Shuguang Tan   +14 more
wiley   +1 more source

Bispecific Antibody Targeting VEGF/TGF‐β Synergizes with Local Radiotherapy: Turning Tumors from Cold to Inflamed and Amplifying Abscopal Effects

Advanced Science, EarlyView.
Y332D, a bispecific antibody that simultaneously blockades VEGF and TGF‐β, counteracted negative RT effects that are attributed to the upregulation of TGF‐β and VEGF, as well as further enhanced the immunostimulatory effects of RT, thereby reprograming the TME from immune “cold” to inflamed state and forming an effective in‐situ vaccine that eradicate ...
Lijuan Lyu, Ming Yi, Ji Chen, Jing Zhang, Xiaobin Ma, Xiaojun Zhang, Liang Zeng, Yan Xue, Haimei Wen, Yujiao Deng, Pengfei Zhou, Kongming Wu, Huafeng Kang, Zhijun Dai   +13 more
wiley   +1 more source

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

Experimental Hematology & Oncology, 2017
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for
Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li, Kongming Wu   +6 more
doaj   +1 more source